WB006

WB006 is an investigational drug initially developed by Whitecap Biosciences and now under the development of Bausch + Lomb following their acquisition of Whitecap Biosciences. The drug is in preclinical development, with its primary indication being geographic atrophy, a severe form of age-related macular degeneration that leads to vision loss. While specific details about the mechanism of action or molecular modality have not been disclosed publicly, WB006 is part of a pipeline focused on novel therapies for eye diseases such as glaucoma and geographic atrophy[1][2][4][6].

Other names

BL1107 sustained release implantBL-1107 sustained release implantBL 1107 sustained release implantBL1107 sustained-release implantBL-1107 sustained-release implantBL 1107 sustained-release implant